Update on the pharmacogenetics of the vitamin D receptor and osteoporosis

Pharmacogenomics

Volumn 10, Issue 3, 2009, Pages 417-433

  Gennari, Luigi ^a   Merlotti, Daniela ^a   De Paola, Vincenzo ^a   Martini, Giuseppe ^a   Nuti, Ranuccio ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Bone mineral density; Calcium; Fractures; Osteoporosis; Pharmacogenetics; Pharmacogenomics; Vitamin D; Vitamin D receptor

Indexed keywords

AROMATASE; CALCITRIOL; CALCIUM; COLLAGEN TYPE 1; ESTROGEN RECEPTOR ALPHA; ETIDRONIC ACID; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; PLACEBO; RALOXIFENE; VITAMIN D; VITAMIN D RECEPTOR; ZOLEDRONIC ACID; CALCITRIOL RECEPTOR;

AGE; BONE DENSITY; BONE TURNOVER; CALCIUM INTAKE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DNA POLYMORPHISM; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HUMAN; OSTEOPOROSIS; PHARMACOGENETICS; PHARMACOGENOMICS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK ASSESSMENT; SINGLE DRUG DOSE; VERTEBRA FRACTURE; VITAMIN D METABOLISM; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION; 3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; BONE; BONE DEVELOPMENT; BONE MINERALIZATION; GENETICS; METHODOLOGY; PHYSIOLOGY; POSTMENOPAUSE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

3' UNTRANSLATED REGIONS; 5' UNTRANSLATED REGIONS; BONE AND BONES; BONE DEVELOPMENT; CALCIFICATION, PHYSIOLOGIC; CALCITRIOL; CALCIUM; HUMANS; OSTEOPOROSIS; PHARMACOGENETICS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POSTMENOPAUSE; RECEPTORS, CALCITRIOL; VITAMIN D;

EID: 65649151302     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.10.3.417     Document Type: Review

References (133)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy: Osteoporosis Prevention, Diagnosis, and Therapy. JAMA 285 (6), 785-795 (2001).
2. Melton LJ 3rd, Thamer M, Ray NF et al.: Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J. Bone Miner. Res. 12 (1), 16-23 (1997).
3. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA: Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353(9156), 878-882 (1999).
4. Dennison E, Mohamed MA, Cooper C: Epidemiology of osteoporosis. Rheum. Dis. Clin. N. Am. 32(4), 617-629 (2006).
5. Melton LJ 3rd, Atkinson EJ, Cooper C, O'Fallon WM, Riggs BL: Vertebral fractures predict subsequent fracture. Osteoporos. Int. 10(3), 214-221 (1999).
6. Sambrock P, Cooper C: Osteoporosis. Lancet 367(9527), 2010-2018 (2006).
7. Cummings SR, Black DM, Nevitt MC et al.: Bone density at various sites for prediction of hip fractures. Lancet 341(8837), 72-75 (1993).
8. Hui SL, Slemenda CW, Carey MA, Johnston CC: Cloosing between predictors of fractures. J. Bone Miner. Res. 10 (11), 1816-1822 (1995).
9. Cummings SR, Black DM, Nevitt MC et al.: Appendicular bone density and age predict hip fracture in women: the study of Osteoporotic Fractures Research Group. JAMA 263 (5), 665-668 (1990).
10. Schuit SC, van der Klift M, Weel AE et al.: Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34(1), 195-202 (2004).
11. Siris ES, Brenneman SK, Barrett-Connor E et al.: The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos. Int. 17(4), 565-574 (2006).
12. Makovey J, Nguyen TV, Naganathan V, Wark JD, Sambrook PN: Genetic effects on bone loss in peri- and postmenopausal women: a longitudinal twin study. J. Bone Miner. Res. 22(11), 1773-1780 (2007).
13. Riggs BL, Khosla S, Melton LJ III: A unitary model of involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J. Bone Miner. Res. 13(5), 763-773 (1998).
14. Johnston CC Jr, Slemenda CW: Changes in skeletal tissue during the aging process. Nutr. Rev. 50(12), 385-387 (1992).
15. Pocock NA, Eisman JA, Hopper I, Yeates MG, Sambrook PN, Eber S: Genetic determinants of bone mass in adults, J Clin. Invest. 80 (3), 706-710 (1987).
16. Eisman JA: Genetics of osteoporosis. Endocr. Rev. 20(6), 788-804 (1999).
17. Ralston SH, Crombrugghe B: Genetic regulation of bone mass and susceptibility to osteoporosis. Genes. Dev. 20(18), 2492-2506 (2006).
18. Seeman E, Hopper JL, Bach LA et al.: Reduced bone mass in daughters of women with osteoporosis. N. Engl. J. Med. 320(9), 554-558 (1989).
19. Soroko SB, Barrett-Connor E, Edelstein SL, Kritz-Silverstein D: Family history of osteoporosis and bone mineral density at the axial skeleton: the Rancho Bernardo Study. J. Bone Miner. Res. 9 (6), 761-769 (1994).
20. Cummings SR, Nevitt MC, Browner WS et al.: Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N. Engl. J. Med. 332(12), 767-773 (1995).
21. Slemenda CW, Christian JC, Williams CJ, Norton JA, Johnston CC Jr: Genetic determinants of bone mass in adult women: a reevaluation of the twin model and the potential importance of gene interaction on heritability estimates. J. Bone Miner. Res. 6(6), 561-567 (1991).
22. Smith EP, Boyod J, Frank GR et al.: Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. N. Engl. J. Med. 331(16), 1056-1061 (1994).
23. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K: Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J. Clin. Endocrinol. Metab. 80(12), 3689-3699 (1995).
24. Gong Y, Slee RB, Fukai N et al.: Osteoporosis-Pseudoglioma Syndrome Collaborative Group: LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107(4), 513-523 (2001).
25. Mani A, Radhakrishnan J, Wang H et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 315 (5816), 1278-1282 (2007).
26. Koay MA, Brown MA: Genetic disorders of the LRP5-Wnt signalling pathway affecting the skeleton. Trends Mol. Med. 3, 129-137 (2005).
27. Byers PH, Wallis GA, Willing MC: Osteogenesis imperfecta: translation of mutation to phenotype. Med. Genet. 28, 433-442 (1991).
28. Peacock M, Koller DL, Fishburn T et al.: Sex-specific and non-sex-specific quantitative trait loci contribute to normal variation in bone mineral density in men. J. Clin. Endocrinol. Metab. 90(5), 3060-3066 (2005).
29. Huang QY, Recker RR, Deng HW. Searching for osteoporosis genes in the post-genome era: progress and challenges. Osteoporos. Int. 14(9), 701-715 (2003).
30. Newton-Cheh C, Hirschhorn JN: Genetic association studies of complex traits: design and analysis issues. Mutat. Res. 573(1-2), 54-69 (2005).
31. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG: Meta-analysis of genome-wide linkage studies for bone mineral density. J. Hum. Genet. 51(5), 480-486 (2006).
32. Gennari L, Bechrini L, Falchetti A, Masi L, Massart F, Brandi ML: Genetics of osteoporosis: role of steroid hormone receptor gene polymorphisms. J. Steroid Biochem. Mol. Biol. 81(1), 1-24 (2002).
33. Liu Yz, Liu YJ, Recker RR et al.: Molecular studies of identification of genes for osteoporosis: the 2002 update. J. Endocrinol. 177(2), 147-196 (2003).
34. Albaga OME, Ralston SH: Genetics of osteoporosis. Rheum. Dis. Clin. N. Am. 32(4), 659-680 (2006).
35. Hirschhorn JN, Daly MJ: Genome-wide association studies for common diseases and complex traits. Nat. Rev. Genet. 6(2), 95-108 (2005).
36. Hirschhorn JN, Gennari L: Bona fide genetic associations with bone mineral density. N. Engl. J. Med. 358(22), 2403-2405 (2008).
37. Kiel DP, Demissie S, Dupuis J, Lunetta KL, Murabito JM, Karasik D: Genome-wide association with bone mass and geometry in the Framingham Heart Study. BMC Med. Genet. 8(1), S14 (2007).
38. Richards JB, Rivadeneira F, Inouye M et al.: Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet 371(9623), 1505-1512 (2008).
39. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S et al.: Multiple genetic loci for mineral density and fracture. N. Engl. J. Med. 358(22), 2355-2365 (2008).
40. Zmuda JM, Kammerer CM: Snipping away at osteoporosis susceptibility. Lancet 371(9623), 1479-1480 (2008).
41. Gennari L, Merlotti D, Martini G, Valleggi F, De Paola V, Nuti R: Vitamin D and its metabolites in the pathogenesis and treatment of osteoporosis: Clinical Cases in Bone and Mineral Metabolism 3(1), 23-34 (2006).
42. Holick MF: Vitamin D: a millennium perspective. J. Cell Biochem. 88(2), 296-307 (2003).
43. Haussler MR, Whitfield GK, Haussler CA et al.: The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J. Bone Miner. Res. 13(3), 325-349 (1998).
44. Jurutka PW, Whitfield GK, Hsieh JC, Thompson PD, Haussler CA, Haussler MR: Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev. Endocr. Metab. Disord. 2 (2), 203-216 (2001).
45. Boyan BD, Schwartz Z: Rapid vitamin D-dependent PKC signaling shares features with estrogen-dependent PKC signaling in cartilage and bone. Steroids 69(8-9), 591-597 (2004).
46. Bianda T, Hussain MA, Glatz Y, Bouillon R, Froesch ER, Schmid C: Effects of short-term insulin-like growth factor-I or growth hormone treatment on bone turnover, renal phosphate reabsorption and 1,25 dihydroxyvitamin D3 production in healthy man. J. Intern. Med. 241(2), 143-150 (1997).
47. Caverzasio J, Montessuit C, Bonjour JP: Stimulatory effect of insulin-like growth factor-1 on renal Pi transport and plasma 1,25-dihydroxy-vitamin D3. Endocrinology 127(1), 453-459 (1990).
48. Christakos S, Liu Y, Dhawau P, Peng X: The calbindins: calbindin D9k and calbindin D28k. In: Vitamin D 2nd Edition. Feldman D, Pike JW, Glorieux FH (Eds). Elsevier, London, UK, 721-735 (2005).
49. Beckerman P, Silver J: Vitamin D and the parathyroid. Am. J. Med. Sci. 317(6), 363-369 (1999).
50. van Driel M, Pols HA, van Leeuwen JP: Osteoblast differentiation and control by vitamin D and vitamin D metabolites. Curr. Pharm. Des. 10(21), 2535-2555 (2004).
51. Baldock PA, Thomas GP, Hodge JM et al.: Vitamin D action and regulation of bone remodeling: suppression of osteoclastogenesis by the mature osteoblast. J. Bone Miner. Res. 21(10), 1618-1626 (2006).
52. Mee AP, Hoyland JA, Braidman IP, Freemont AG, Davies M, Mawer EB: Demonstration of vitamin D receptor transcripts in actively resorbing osteoclasts in bone sections. Bone 18 (4), 295-299 (1996).
53. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B: Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 293(18), 2257-2264 (2005).
54. Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P: Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J. Clin. Endocrinol. Metab. 92(4), 1415-1423 (2007).
55. Mosekilde L: Vitamin D and the elderly. Clin. Endocrinol. 62(3), 265-281 (2005).
56. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunieur PJ, Vieth R: Estimates of optimal vitamin D status. Osteoporos. Int. 16(7), 713-716 (2005).
57. Heaney RP: Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am. J. Clin. Nutr. 80(6), S1706-S1709 (2004).
58. Holick MF: Vitamin D deficiency. N. Engl. J. Med. 357(3), 266-281 (2007).
59. Venning G: Recent developments in vitamin D deficiency and muscle weakness among elderly people, Br. Med. J. 330(7490), 524-526 (2005).
60. Pfeifer M, Bergerow B, Minne HW: Vitamin D and muscle function. Osteoporos. Int. 13(3), 187-194 (2002).
61. Morrison NA, Yeoman R, Kelly PJ, Eisman JA: Contribution of trans-acting factors alleles to normal physiological variability: vitamin D receptor gene polymorphisms and circulating osteocalcin. Proc. Natl Acad. Sci. USA 89(15), 6665-6669 (1992).
62. Morrison NA, Qi JC, Akifumi T et al.: Prediction of bone density from vitamin D receptor alleles. Nature 367(6460), 284-287 (1994).
63. Uitterlinden AG, Fang Y, van Meurs JBJ, Pols HAP, van Leeuwen JPTM: Genetics and biology of vitamin D receptor polymorphisms. Gene 338(2), 143-156 (2004).
64. Gross C, Eccleshall TR, Malloy PJ, Villa ML, Marcus R, Feldman D: The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women. J. Bone Miner. Res. 11(12), 1850-1855 (1996).
65. Arai H, Miyamoto KI, Yoshida M et al.: The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene. J. Bone Miner. Res. 6(7), 1256-1264 (2001).
66. Arai H, Miyamoto K, Taketani Y et al.: A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J. Bone Miner. Res. 12(6), 915-921 (1997).
67. Fang Y, van Meurs JB, Bergink AP et al.: Cdx-2 polymorphism in the promoter region of the human vitamin D receptor gene determines susceptibility to fracture in the elderly. J. Bone Miner. Res. 18(9), 1632-1641 (2003).
68. Morita A, Iki M, Dohi Y et al.: Effects of the Cdx-2 polymorphism of the vitamin D receptor gene and lifestyle factors on bone mineral density in a representative sample of Japanese women: the Japanese Population-based Osteoporosis (JPOS) Study. Calcif. Tissue Int. 77(6), 339-347 (2005).
69. Willing M, Sowers M, Aron, D et al.: Bone mineral density and its change in white women: estrogen and vitamin D receptor genotypes and their interaction. J. Bone Miner. Res. 13(4), 695-705 (1998).
70. Gennari L, Becherini L, Masi L et al.: Vitamin D and estrogen receptor allelic variants in post-menopausal women: evidence of multiple gene contribution on bone mineral density. J. Clin. Endocrinol. Metab. 83(3), 939-944 (1998).
71. Deng HW, Li J, Li JL et al.: Change of bone mass in post-menopausal Caucasian women with and without hormone replacement therapy is associated with vitamin D receptor and estrogen receptor genotypes. Hum. Genet. 103(5), 576-585 (1998).
72. Giguere Y, Dodin S, Blancher C, Morgan K, Rousseau F: The association between heel ultrasound and hormone replacement therapy is modulated by a two-locus vitamin D and estrogen receptor genotype. J Bone Miner. Res. 15(6), 1076-1084 (2000).
73. Suarez F, Rossignol C, Garabedian M: Interactive effect of estradiol and vitamin D receptor gene polymorphisms as a possible determinant of growth in male and female infants. J. Clin. Endocrinol. Metab. 83(10), 3563-3568 (1998).
74. Cooper GS, Umbach DM: Are vitamin D receptor polymorphisms associated with bone mineral density? A meta-analysis. J. Bone Miner. Res. 11(12), 1841-1849 (1996).
75. Gong G, Stern HS, Cheng SC et al.: The association of bone mineral density with vitamin D receptor gene polymorphisms. Osteoporos. Int. 9(1), 55-64 (1999).
76. Thakkinstian A, D'este C, Eisman J, Nguyen T, Atria J: Meta-analysis of molecular association studies: vitamin D receptor gene polymorphisms and BMD as a case study: J, Bone Miner. Res. 19(3), 419-428 (2004).
77. Fang Y, Rivadeneira F, van Meurs JBJ, Pols HAP, Ioannidis JPA, Uitterlinden AG: Vitamin D receptor gene BsmI and TaqI polymorphisms and fracture risk: a meta-analysis. Bone 39(4), 938-945 (2006).
78. Macdonald HM, Mcguigan FE, Stewart A et al.: Large-scale population-based study shows no evidence of association between common polymorphisms of the VDR gene and BMD in British women. J Bone Miner. Res. 21(1), 151-162 (2006).
79. Uitterlinden AG, Ralston SH, Brandi ML et al.: Large-scale analysis of association between common vitamin D receptor gene variations and osteoporosis: the GENOMOS study. Ann. Int. Med. 145(4), 255-264 (2006).
80. Fang Y, van Meurs JB, d'Alesio A et al.: Promoter and 3′-untranslated-region haplotypes in the vitamin D receptor gene predispose to osteoporotic fracture: the Rotterdam Study. Am. J. Hum. Genet. 77(5) 807-823 (2005).
81. Grundberg E, Lau EM, Pastinen T et al.: Vitamin D receptor 3′ haplotypes are unequally expressed in primary human bone cells and associated with increased fracture risk: the MrOS Study in Sweden and Hong Kong. J. Bone Miner. Res. 22(6), 832-840 (2007).
82. Fang Y, van Meurs JB, Rivadeneira F et al.: Vitamin D receptor gene haplotype is associated with body height and bone size. J. Clin. Endocrinol. Metab. 92(4), 1491-1501 (2007).
83. Gennari L, De Paola V, Merlotti D, Martini G, Nuti R: Steroid hormone receptor gene polymorphisms and osteoporosis: a pharmacogenomic review. Expert. Opin. Pharmacother. 8(5), 537-553 (2007).
84. Ferrari SL, Bonjour JP, Rizzoli R: The vitamin D receptor gene and calcium metabolism. Trends Endocrinol. Metab. 9(7), 259-264 (1998).
85. Ferrari SL, Rizzoli R, Slosman DO, Bonjour JP: Do dietary calcium and age explain the controversy surrounding the relationship between bone mineral density and vitamin D receptor gene polymorphisms? J. Bone Miner. Res. 13(3), 363-370 (1998).
86. Krall EA, Parry P, Lichter JB, Dawson-Hughes B: Vitamin D receptor alleles and rates of bone loss: influences of years since menopause and calcium intake. J. Bone Miner. Res. 10(6), 978-984 (1995).
87. Ferrari S, Rizzoli R, Chevallery T, Slosman D, Eisman JA, Bonjour JP: Vitamin D receptor gene polymorphisms and change in lumbar spine bone mineral density. Lancet 345(8947), 423-424 (1995).
88. Kiel DP, Myers RH, Cupples LA et al.: The Bsm 1 vitamin D receptor restriction fragment length polymorphism (bb) influences the effect of calcium intake on bone mineral density. J. Bone Miner. Res. 12(7), 1049-1057 (1997).
89. Salamone LM, Glynn NW, Black DM et al.: Determinants of pre-menopausal bone mineral density: the interplay of genetic and lifestyle factors. J Bone Miner. Res. 11(10), 1557-1565 (1996).
90. Shiekh M, Ramirez A, Emmett M, Santa Ana C, Fordtran J: Role of vitamin D dependent and vitamin D independent mechanisms in absorption of food calcium. J. Clin. Invest. 81(1), 126-132 (1988).
91. Dawson-Hughes B, Harris SS, Finneran S: Calcium absorption on high and low calcium intake in relation to Vitamin D receptor genotype. J. Clin. Endocrinol. Metab. 80(10), 3657-3661 (1995).
92. Wishart JM, Horowitz M, Need AG et al.: Relations between calcium intake, calcitriol, polymorphisms of vitamin D receptor gene and calcium absorption in pre-menopausal women. Am. J. Clin. Nutr. 65(3), 798-802 (1997).
93. Gennari L, Becherini L, Masi L et al.: Vitamin D receptor genotypes and intestinal calcium absorption in post-menopausal women. Calcif. Tissue Int. 61(6), 460-463 (1997).
94. Ames SK, Ellis KJ, Gunn SK, Copeland KC, Abrams SA: Vitamin D receptor gene Fok I polymorphism predicts calcium absorption and bone mineral density in children. J. Bone Miner. Res. 14(5), 740-746 (1999).
95. Barger Lux MJ, Heaney RP, Hayes J, De Luca HF, Johnson ML, Gong G: Vitamin D receptor gene polymorphisms, bone mass, body size and mucosal VDR density. Calcif. Tissue Int. 57(2), 161-162 (1995).
96. Kinyamu HK, Gallagher JC, Knezetic JA, De Luca HF, Prahl JM, Lanspa SJ: Effect of vitamin D receptor genotypes on calcium absorption, duodenal vitamin D receptor concentration and serum 1,25-dihydroxy-vitamin D levels in normal women. Calcif. Tissue Int. 60(6), 491-495 (1997).
97. Carling T, Kindmark A, Hellman P et al.: Vitamin D receptor genotypes in primary hyperparathyroidism. Nature Med. 1(12), 1309-1311 (1995).
98. Carling T, Ridefelt P, Hellman P, Rastad J, Akerstrom G: Vitamin D receptor polymorphisms correlate to parathyroid cell function in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 82(6), 1772-1775 (1997).
99. Yokoyama K, Shigematsu T, Tsukada T et al.: Apa I polymorphism in the vitamin D receptor gene may affect the parathyroid response in Japanese with end-stage renal disease. Kidney Intl 53(2), 454-458 (1998).
100. McClure L, Eccleshall TR, Gross C et al.: Vitamin D receptor polymorphisms, bone mineral density, and bone metabolism in postmenopausal Mexican - American women. J. Bone Miner. Res. 12(2), 234-240 (1997).
101. Ferrari S, Manen D, Bonjour JP, Slosman D, Rizzoli R: Bone niincral mass and calcium and phosphate metabolism in young men: relationship with vitamin D receptor allelic polymorphisms. J. Bone Miner. Res. 84(6), 2043-2048 (1999).
102. Michaelsson K, Wolk A, Jacobsson A et al.: The positive effect of dietary vitamin D intake on bone mineral density in men is modulated by the polyadenosine repeat polymorphism of the vitamin D receptor. Bone 39(6), 1343-1351 (2006).
103. Yamagata Z, Miyamura T, Iijima S et al.: Vitamin D receptor gene polymorphism and bone mineral density in healthy Japanese women. Lancet 344(8928), 1027 (1994).
104. Howard C, Nguyen T, Morrison N et al.: Genetic influences on bone density: physiological correlates of vitamin D receptor gene alleles in premenopausal women. J. Clin. Endocrinol. Metab. 80(9), 2800-2805 (1995).
105. Matsuyama T, Ishii S, Tokita A et al.: Vitamin D receptor genotypes and bone mineral density. Lancet 345(8959), 1238-1239 (1995).
106. Graafmans WC, Lips P, Ooms ME, van Leeuwen JP, Pols HA, Uitterlinden AG: The effect of vitamin D supplementation on the bone mineral density of the femoral neck is associated with vitamin D receptor genotype. J. Bone Miner. Res. 12(8), 1241-1245 (1997).
107. Hunter D, Major P, Arden N et al.: A randomized controlled trial of vitamin D supplementation on preventing postmenopausal bone loss and modifying bone metabolism using identical twin pairs. J. Bone Miner. Res. 15(11), 2276-2283 (2000).
108. Morrison NA, George PM, Vaughan T, Tilyard MW, Frampton CM, Gilchrist NL: Vitamin D receptor genotypes influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis. Pharmacogenet. Genomics 15(2), 127-135 (2005).
109. Palomba S, Orio F Jr, Russo T et al.: BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporos. Int. 16(8), 943-952 (2005).
110. Mocharla H, Butch AW, Pappas AA et al.: Quantification of vitamin D receptor mRNA by competitive polymerase chain reaction in PBMC: lack of correspondence with common allelic variants. J. Bone Miner. Res. 12, 726-733 (1997).
111. Verbeek W, Gombart AF, Shiohara M, Campbell M, Koeffler HP: Vitamin D receptor: no evidence for allele-specific mRNA stability in cells which are heterozygous for the TaqI restriction enzyme polymorphism. Biochem. Biophys. Res. Commun. 238(1), 77-80 (1997).
112. Carling T, Rastad J, Akerstrom, G, Westin G: Vitamin D receptor (VDR) and parathyroid hormone messenger ribonucleic acid levels correspond to polymorphic VDR alleles in human parathyroid tumors. J. Clin. Endocrinol. Metab. 83(7), 2255-2259 (1998).
113. Gross C, Musiol IM, Eccleshall TR, Malloy PJ, Feldman D: Vitamin D receptor gene polymorphisms: analysis of ligand binding and hormone responsiveness in cultured skin fibroblasts. Biochem. Biophys. Res. Commun. 242(3), 467-473 (1998).
114. Durrin LK, Haile RW, Ingles SA, Coetzee GA: Vitamin D receptor 3′-untranslated region polymorphisms: lack of effect on mRNA stability. Biochim. Biophys. Acta 1453(3), 311-320 (1999).
115. Yamagata M, Nakajima S, Tokita A et al.: Analysis of the stable levels of messenger RNA derived from different polymorphic alleles in the vitamin D receptor gene. J. Bone Miner. Metab. 17(3), 164-170 (1999).
116. Colin EM, Weel AE, Uitterlinden AG et al.: Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1, 25-dihydroxyvitamin D3. Clin. Endocrinol. (Oxf.) 52(2), 211-216 (2000).
117. Ohtera K, Ishii S, Matsuyama T: Influence of the vitamin D receptor alleles on human osteoblast-like cells. J. Bone Joint Surg. Br. 83(1), 134-138 (2001).
118. Ingles SA, Haile RW, Henderson BE et al.: Strength of linkage disequilibrium between two vitamin D receptor markets in five ethnic groups: implications for association studies. Cancer Epidemiol. Biomarkers Prev. 6(2), 93-98 (1997).
119. Gross C, Krishnan AV, Malloy PJ, Eccleshall TR, Zhao XY, Feldman D: The vitamin D receptor start codon polymorphism: a functional analysis of Fok I variants. J. Bone Miner. Res. 13(11), 1691-1699 (1998).
120. Correa P, Rastad J, Schwarz P et al.: The vitamin D receptor ( VDR) start codon polymorphism in primary hyperparathyroidism and parathyroid VDR messenger ribonucleic acid levels. J. Clin. Endocrinol. Metab. 84(5), 1690-1694 (1999).
121. Jurutka PW, Remus LS, Whitfield GK et al.: The polymorphic N-terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol. Endocrinol. 14(3), 401-420 (2000).
122. Whitfield GK, Remus LS, Jurutka PW et al.: Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol. Cell. Endocrinol. 177(1-2), 145-159 (2001).
123. Suh E, Chen L, Taylor J, Traber PG: A homeodomain protein related to caudal regulates intestine-specific gene transcription. Mol. Cell. Biol. 4(11), 7340-7351 (1994).
124. Crofts L, Hancock M, Morrison N, Eisman J: Multiple promoters direct the tissue specific expression of novel N-terminal variant human vitamin D receptor gene transcripts. Proc. Natl Acad. Sci. USA 95(18), 10529-10534 (1998).
125. Rebbeck TR, Spitz M, Wu X: Assessing the function of genetic variants in candidate gene association studies. Nat. Rev. Genet. 5(8), 589-597 (2004).
126. Venter JC, Adams MD, Myers EW et al.: The sequence of the human genome. Science 291(5507), 1304-1351 (2001).
127. Marc J, Prezelj J, Komel R, Kocijancic A: VDR genotype and response to etidronate therapy in late postmenopausal women. Osteoporos. Int. 10(4), 303-306 (1999).
128. Palomba S, Numi FG, Mossetti G et al.: Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with BsmI vitamin D receptor genotypes. Clin. Endocrinol. 58(3), 365-371 (2003).
129. Otrock ZK, Mahfouz RA, Charafeddine KM, Rayes RF, Zahed LF, Taher AT: Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis. Ann. Hematol. 87(11), 947-948 (2008).
130. Deng HW, Li J, Li JL et al. Change of bone mass in postmenopausal Caucasian women with and without hormone replacement therapy is associated with vitamin D receptor and estrogen receptor genotypes. Hum. Genet. 103, 576-585 (1998).
131. Giguère Y, Dodin S, Blancher C, Morgan K, Rousseau F: The association between heel ultrasound and hormone replacement therapy is modulated by a two-locus vitamin D and estrogen receptor genotype. J. Bone Miner. Res. 15(6), 1076-1084 (2000).
132. Kurabayashi T, Matsushita H, Tomita M et al. Association of vitamin D and estrogen receptor gene polymorphism with the effects of longterm hormone replacement therapy on bone mineral density. J. Bone Miner. Metab. 22(3), 241-247 (2004).
133. Bracco L, Kearsey J: The relevance of alternative RNA splicing to pharmacogenomics. Trends Biotechnol. 21, 346-353 (2003).